Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.bbrc.2020.04.034 http://scihub22266oqcxt.onion/10.1016/j.bbrc.2020.04.034 32327257!7152910!32327257     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biochem+Biophys+Res+Commun 2020 ; 526 (4): 1143-1149 Nephropedia Template TP {{tp|p=32327257|t=2020. Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication |pdf=|usr=}}{{32327257}} gab.com Text Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication JO: Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=32327257 #FOAvip In this study, we examined the impact of roscovitine, a cyclin-dependent kinase inhibitor (CDKI) that has entered phase I and II clinical trials, on influenza A viruses (IAVs) and its antiviral mechanism. The results illustrated that roscovitine inhibited multiple subtypes of influenza strains dose-dependently, including A/WSN/1933(H1N1), A/Aichi/2/68 (H3N2) and A/FM1/47 (H1N1) with IC(50) value of 3.35 +/- 0.39, 7.01 +/- 1.84 and 5.99 +/- 1.89 muM, respectively. Moreover, roscovitine suppressed the gene transcription and genome replication steps in the viral life cycle. Further mechanistic studies indicated that roscovitine reduced viral polymerase activity and bound specifically to the viral PB2cap protein by fluorescence polarization assay (FP) and surface plasmon resonance (SPR). Therefore, we believed roscovitine, as a PB2cap inhibitor, was a prospective antiviral agent to be developed as therapeutic treatment against influenza A virus infection. Twit Text FOAVip Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication ????Biochem Biophys Res Commun http://www.kidney.de/pget.php?&tw=1&pmid=32327257 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32327257 #FOAvip English Wikipedia <ref>{{Cite pmid|32327257}}</ref> Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against influenza a virus replication #MMPMID32327257 Huang Q; Zhong Y; Li J; Ye Y; Wu W; Chen L; Feng M; Yang J; Liu S Biochem Biophys Res Commun 2020[Jun]; 526 (4): 1143-1149 PMID32327257show ga In this study, we examined the impact of roscovitine, a cyclin-dependent kinase inhibitor (CDKI) that has entered phase I and II clinical trials, on influenza A viruses (IAVs) and its antiviral mechanism. The results illustrated that roscovitine inhibited multiple subtypes of influenza strains dose-dependently, including A/WSN/1933(H1N1), A/Aichi/2/68 (H3N2) and A/FM1/47 (H1N1) with IC(50) value of 3.35 +/- 0.39, 7.01 +/- 1.84 and 5.99 +/- 1.89 muM, respectively. Moreover, roscovitine suppressed the gene transcription and genome replication steps in the viral life cycle. Further mechanistic studies indicated that roscovitine reduced viral polymerase activity and bound specifically to the viral PB2cap protein by fluorescence polarization assay (FP) and surface plasmon resonance (SPR). Therefore, we believed roscovitine, as a PB2cap inhibitor, was a prospective antiviral agent to be developed as therapeutic treatment against influenza A virus infection. |Animals[MESH] |Antiviral Agents/*pharmacology[MESH] |DNA-Directed RNA Polymerases/metabolism[MESH] |Dogs[MESH] |Genome, Viral[MESH] |Humans[MESH] |Influenza A virus/drug effects/genetics/*physiology[MESH] |Madin Darby Canine Kidney Cells[MESH] |Protein Kinase Inhibitors/chemistry/*pharmacology[MESH] |RNA Cap-Binding Proteins/*metabolism[MESH] |RNA-Dependent RNA Polymerase/*metabolism[MESH] |Roscovitine/chemistry/*pharmacology[MESH] |Transcription, Genetic/drug effects[MESH] |Viral Proteins/*metabolism[MESH] |Virus Internalization/drug effects[MESH]Kinase inhibitor roscovitine as a PB2 cap-binding inhibitor against in(epmc).pdf DeepDyve Pubget Overpricing